VMD VIEMED HEALTHCARE, INC.

NEUTRAL Impact: 3/10 8-K
Horizon immediate Filed Jun 4, 2026 Processed 2d 2h ago SEC 0001729149-26-000034
8-K context-dependent: Items 5.02

Price Chart

Loading chart...

Executive Summary

Viemed Healthcare filed an 8-K reporting the results of its June 4, 2026 Annual General and Special Meeting. Shareholders approved all proposals: election of all seven director nominees (with Sabrina Heltz receiving 20.24% withheld votes), ratification of Ernst & Young as auditors, an advisory say-on-pay vote, and a second amendment to the 2024 Long Term Incentive Plan increasing the share reserve to 7,696,717 common shares. This is a routine governance filing with no material financial impact.

Actionable Insight

Routine annual meeting results with no surprises. The 20.24% withhold vote for director Sabrina Heltz is notable but not actionable without further context. Monitor for any future equity grant disclosures under the expanded LTIP share reserve.

Key Facts

  • Shareholders approved a second amendment to the 2024 LTIP, increasing the maximum share reserve to 7,696,717 common shares (including up to 1,000,000 for incentive stock options).
  • All seven director nominees were elected; Sabrina Heltz received the highest withhold vote at 20.24%.
  • Ernst & Young LLP was ratified as independent auditors for FY2026 with 97.59% of votes for.
  • Advisory say-on-pay vote passed with 93.21% support.
  • Broker non-votes totaled 5,139,303 for director elections and the LTIP amendment.

Financial Impact

No financial figures reported. The LTIP amendment increases authorized shares for equity compensation but does not represent immediate dilution or cash impact.

dilution

Risk Factors

  • Potential future dilution from equity awards under the expanded LTIP.
  • Elevated withhold vote for Sabrina Heltz (20.24%) may indicate shareholder governance concerns.

Market Snapshot

Exchange
Nasdaq
Sector
Services-Misc Health & Allied Services, NEC
Analyst Consensus
83% bullish (6 analysts)

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001729149-26-000034
Document: secondamendmentviemedhealt.htm0001729149-26-000034
Document: 0001729149-26-000034-index-headers.html0001729149-26-000034
Document: 0001729149-26-000034-index.html0001729149-26-000034
Document: 0001729149-26-000034.txt0001729149-26-000034
4 reports for VMD
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for VMD — sortable, filterable
Type Now
Jun 4, 2026
2d ago
8-K
NEUTRAL ★ 3/10
awaiting T+20
Jun 2, 2026
4d ago
8-K
NEUTRAL ★ 5/10
awaiting T+20
May 5, 2026
4w ago
8-K
MIXED ★ 5/10
$8.52 $9.56▲ +12.27%▲ +9.49%$9.97 (+17.09%)
Mar 4, 2026
13w ago
8-K
BULLISH ★ 8/10
$8.40 $9.63▲ +14.64%▲ +18.43%$9.97 (+18.69%)
Showing 4 of 4

US Market Status

Market Closed — Opens Mon (14h 47m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access